A six-year-old girl from Eritrea who was born with a rare genetic disease that causes blindness has regained her sight after receiving an innovative gene therapy in Israel. https://youtu.be/v8NLQEX3ViM Radical new gene therapy restores sight to patients with rare eye condition Galila Yohannes was diagnosed with retinitis pigmentosa (RP), a condition that affects the retina…
With £96 million Series A financing, Lifescience company developer Syncona has launched Beacon Therapeutics Holdings, a leading ophthalmic gene therapy company focused on restoration and improvement of vision of patients with retinal diseases. Click to read more.
Beacon Therapeutics launches with £96 million ($120 million) to develop a new generation of gene therapies for retinal diseases resulting in blindness streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
New leading gene therapy company created combining late-stage X-linked retinitis pigmentosa program from AGTC, a preclinical program spun out from the University of Oxford and a second. | June 12, 2023
Beacon Therapeutics spun out by Syncona and Oxford raises £96 million for retinal gene therapy ox.ac.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ox.ac.uk Daily Mail and Mail on Sunday newspapers.